FDA Forum to Promote Progress in Computational Science from Regulatory and Product Development Perspectives

One of the most important and unrecognized issues contributing to drug development and regulatory productivity and quality is the ability to acquire, store, analyze, share and report information needed to make the most informed and rapid decisions in pharmaceutical companies, contract research organizations, and international regulatory agencies. This meeting will review progress on topics such as data standards, best practices-driven analytical tool development, business processes driving information systems development, and user experience/evaluation of current tools.

Highlights

- Breakout Sessions:
  - Nonclinical preapproval
  - Clinical preapproval
  - Postmarket safety
  - Product quality
  - Data quality

- Formation of ongoing Working Groups to address computational science issues and solutions from the Breakout Sessions

- Poster Presentations

- Interactive Exhibit Hall

- Software Showcase and Demonstrations: SDTM Validation Tool Demo- please refer to the Exhibitor Summary to identify which companies are participating in this demonstration

continued
Featured Topics
- Quality metrics and cases regarding data submission quality
- Processes and tools designed to assure adequate data quality supporting a successful review
- Specifications for new tools
- Effectiveness of current tools
- Need-driven levels of tool training
- Impact of processes and tools on problem-solving quality, efficiency, and cost
- Regulatory data submissions that are efficiently loaded into the JANUS warehouse
- FDA and sponsor needs and plans
- Development of a bioinformatics FDA platform enabling electronic regulatory review of routine submissions and emerging safety and product quality concerns

Who Should Attend
- Physicians
- Biostatisticians
- Epidemiologists
- Clinical pharmacologists
- Data management professionals
- Information technology professionals
- Pharmaceutical industry (preclinical, premarket, postmarket development, regulatory, IT) professionals
- Contract research organizations

Call for Poster Abstracts

Suggested Poster Abstract Topics
- Data submission standards development, implementation, and best practices
- User experience/evaluation of current processes and tools and the subsequent impact on organizational performance
- Needs and specifications for proposed new tools and processes
- Business processes driving information systems development
- Impact of processes and tools on problem solving quality, efficiency, and cost

Poster Abstract Submission Guidelines
Please submit all poster abstracts using the online form at:
http://www.diahome.org/DIAHOME/GetInvolved/
AbstractSubmissionLauncher.aspx
All abstracts must be received by March 1, 2010.
Authors of selected abstracts will be notified by March 8, 2010.

General Submission Requirements
(Please read the following instructions carefully; incorrect or incomplete abstracts will not be considered.)

1. All poster presentations must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Mention of drug products must be limited to generic names, with no inclusion of brand names in any area of the poster, including poster titles and handouts. Logos and advertising may not appear anywhere on the poster.

2. Please provide the following information on the website abstract form:
   - Author Information: Name, Degrees, Job Title, Affiliation, Mailing Address, Phone Number, Fax Number, Email
   - Primary Topic Area

3. Submitted abstracts must include the following sections:
   - Abstract Title (250 characters)
   - Abstract Objective (300 characters)
   - Abstract Method (300 characters)
   - Abstract Results (300 characters)
   - Abstract Conclusion (300 characters)

4. If an abstract is accepted, one author or coauthor must attend the meeting to present the poster.

5. Preference will be given to submitted abstracts that address real-life applications and case studies.

6. Poster boards are four feet high and eight feet wide (4’x8”).

DISCLOSURE INFORMATION
All speakers must disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or providers of commercial services discussed in an educational presentation, as well as any discussion of unlabeled or unapproved drugs or devices.

At the time of electronic submission of abstracts, all speakers must complete the speaker disclosure section of the electronic submission form.

For further information, contact
Benjamin Zaitz, Program Manager
Phone +1.215.293.5803 • Fax +1.215.293.5937
email Benjamin.Zaitz@diahome.org
SUNDAY, MARCH 21, 2010

4:00-6:00 PM REGISTRATION AND EXHIBIT HALL SET-UP

DAY 1 | MONDAY, MARCH 22, 2010

7:15-8:15 AM REGISTRATION AND CONTINENTAL BREAKFAST

8:15-8:30 AM WELCOME AND OPENING REMARKS

8:30-10:00 AM PLENARY SESSION 1

The Current State: Description of Current State, Defining the Gap, 3-year Plans

CHAIRPERSON
ShaAvhree Buckman, MD, PhD, FAAP
Director, Office of Translational Sciences, CDER, FDA

Introduction
ShaAvhree Buckman, MD, PhD, FAAP
Director
Office of Translational Sciences
CDER, FDA

CBER Needs and Plans
Karen Midthun, MD
CBER, FDA

CDER Needs and Plans
Janet Woodcock, MD
Center Director
CDER, FDA

10:00-10:30 AM REFRESHMENT BREAK AND EXHIBITS

10:30 AM-12:00 PM PLENARY SESSION 2

Keynote Presentations

NCI caBIG Scope, Plans and Impact
Ken Buetow, PhD
Associate Director for Bioinformatics and Information Technology
National Cancer Institute, NIH

BTRIS: NIH Biomedical Translational Research Information System
James Cimino, MD
Chief, Laboratory for Informatics Development, NIH

12:00-1:00 PM LUNCHEON AND EXHIBITS

1:00-2:30 PM PLENARY SESSION 3

Data Standards: Working on the Vision and Taking the Next Steps

CHAIRPERSON
Stephen E. Wilson, DrPH, CAPT. USPHS
Director, Division of Biometrics III, CDER, FDA

Data standards are the foundation of almost everything we are trying to do to improve drug development and review. They are needed for the science, the tools, healthcare, and review. To “get there,” to have the standards that we need and will use, we must think about current requirements for review, plan the next steps, use what we have developed and figure out how to continuously improve. This session will bring together representatives from CDER, industry, the vendor community and the data standards organizations to understand what we need to do and how we can collaborate to get the standards that we need, the standards we will use.

Developing a CDER/CSC Data Standards Plan

Presenters
Theresa Mullin, PhD
Director
Office of Planning and Informatics
CDER, FDA

Data Stewardship and the Art and Science of Explaining Standards So That Everyone Gets It
Frank W. Rockhold, PhD
Senior Vice President
Global Clinical Safety and Pharmacovigilance
GlaxoSmithKline

Planning the Clinical Research Program with Your Submission in Mind
Rebecca D. Kush, PhD
President and CEO
CDISC

Panel Discussion

All Session Speakers

For additional information, contact Shannon Lewis, Exhibits Associate
Phone +1.215.442.6149 • Fax +1.215.442.6199 • eMail shannon.lewis@diahome.org

Exhibit Hall Hours

Monday, March 22 9:00 AM-7:00 PM
Networking Reception 5:00-7:00 PM
Tuesday, March 23 9:00 AM-3:45 PM

Coffee breaks, lunch, and the reception will be held in the Exhibit Hall.

Panel Discussion

All Session Speakers

Exhibitors (as of March 4, 2010)

Applied Clinical Trials
Business & Decision Life Sciences
CDISC
Distributed Compliance Solutions
Integrated Clinical Systems, Inc.
Kestrel Consultants, Inc.
Kforce Clinical Research
MaxisIT, Inc.
Octagon Research Solutions, Inc.
OpenCDISC
Phase Forward
RPS, Inc.
Society for Clinical Data Management
Charles Jaffe, MD, PhD  
CEO, Health Level 7 International

Gary Walker  
Associate Director, Enterprise Data Standards  
Quintiles Transnational Corp.

2:30-3:00 PM  REFRESHMENT BREAK AND EXHIBITS

3:00-4:50 PM  PLENARY SESSION 4  
Learning from the NCI caBIG® Experience  
CHAIRPERSON  
Ram Tiwari, PhD  
Associate Director for Statistical Science and Policy, CDER, FDA

The National Cancer Institute initiated its Cancer Biomedical Informatics Grid (caBIG®) program in 2004 as a bold initiative to create “a virtual web of interconnected data, individuals, and organizations that redefines how research is conducted, care is provided, and patients/participants interact with the biomedical enterprise.” NCI recognized that the ability to connect people, organizations, and data through information technology would be critical to fulfilling NCI’s mission and to taking advantage of the research opportunities offered by 21st century science. Two years into its enterprise phase, this session seeks to take one of the several domain areas of caBIG®, that of clinical trials, and present some concrete achievements, including a demonstration of working software created according to the caBIG architecture, as well as to highlight some lessons learned along the way.

John Speakman, MS  
Associate Director for Bioinformatics and Information Technology  
National Cancer Institute, NIH

William T. Dyer, Jr.  
caBIG® Clinical Trials Management Systems Representative  
National Cancer Institute, NIH

Edward D. Helton, PhD, MA  
Associate Director  
Center for Biomedical Informatics and Information Technology  
National Cancer Institute, NIH

Panel Discussion  
All Session Speakers and

Norman Stockbridge, MD, PhD  
Director, Division of Cardiovascular and Renal Products  
CDER, FDA

Robert T. O’Neill, PhD  
Director, Office of Biostatistics  
CDER, FDA

Christoffer Wenzel Tornoe, PhD  
Pharmacometrics Team Leader  
CDER, FDA

Tarek A. Hammad, MD, PhD, MSc, MS  
Associate Director of Epidemiology  
Division of Epidemiology, Office of Surveillance and Epidemiology  
CDER, FDA

Amy Abernethy, MD  
Associate Director, Duke Comprehensive Cancer Center  
Associate Professor of Medicine, Division of Medical Oncology  
Director, Duke Cancer Care Research Program, Duke University

5:00-7:00 PM  NETWORKING RECEPTION AND EXHIBITS

---

DAY 2 | TUESDAY, MARCH 23, 2010

7:30-8:15 AM  REGISTRATION

8:15-9:45 PM  PLENARY SESSION 5  
Janus: Moving Forward and Planning for Transition  
CHAIRPERSON  
Edward D. Helton, PhD, MA  
Associate Director, Center for Biomedical Informatics and Information Technology, National Cancer Institute, NIH

The Janus study data repository is being developed by FDA and the National Cancer Institute (NCI) through an Interagency Oncology Task Force (IOTF) to enable the two organizations to share knowledge and resources to facilitate the development of new drugs and speed their delivery to patients. The Janus data repository is part of a larger effort to implement a common, standards-based electronic infrastructure that supports the submission, validation, data warehousing, access, and analysis of clinical and non-clinical study data. This session will cover technical, planning, and policy aspects of the effort to develop Janus. It will also describe current experiences with Janus at NCTR.

Technical Aspects of the Janus 2.0 Data Model  
Clyde Ulmer  
National Center for Toxicological Research (NCTR), FDA

DA Planning and Policy Aspects of Janus 2.0 Adoption  
Lilliam Rosario, PhD  
Associate Director  
Office of the Chief Scientist  
FDA

Using Janus Server Technology to Improve Public Health  
Edward D. Helton, PhD, MA  
Associate Director  
Center for Biomedical Informatics and Information Technology  
National Cancer Institute, NIH

Christo Andonyadis  
Associate Director, Clinical Trials Application Engineering  
NCI, NIH

Panel Discussion  
All Session Speakers and

Jonathan G. Levine, PhD  
Senior Scientist  
OC/OCPP, FDA

B. Sue Bell, PhD  
Director, CDER Computational Science Center  
CDER, FDA

Wayne Kubick  
Vice President  
PhaseForward, Inc.

9:45-10:15 AM  REFRESHMENT BREAK AND EXHIBITS

---
BREAKOUT SESSION 1
Preapproval – Nonclinical
CHAIRPERSONS
Lilliam Rosario, PhD
Associate Director, Office of the Chief Scientist, FDA
Lauren Murphree Mihalcik, PhD
Pharmacologist, Division of Metabolism and Endocrinology, CDER, FDA
This session will provide a current state of affairs for the review of pharmacology/toxicology information in support of premarket regulatory review of drugs and biologics. The session will provide a forum to share progress on ongoing initiatives including data standards development for animal toxicology data and tool development. The forum will be open to discuss steps forward to address the identified gaps in the current state and identify best practices for proposed tools and solutions.

Current State of Affairs: A Day in the Life of a PT Reviewer - The CDER Perspective
Paul Brown, PhD
Associate Director, Pharmacology and Toxicology, CDER, FDA

Current State of Affairs: A Day in the Life of a PT Reviewer – The CBER Perspective
Steve Kunder, PhD, DABT
Pharmacologist, Office of Vaccine Research and Review, CBER, FDA

Current Initiatives: SEND and ToxVision
Lou Ann Kramer
Eli Lilly and Company
Lauren Murphree Mihalcik, PhD
Pharmacologist, Division of Metabolism and Endocrinology, CDER, FDA
Shree Nath, PhD
VP, Pharmaceuticals, PointCross, Inc.

Future State of Affairs: JANUS - Initiative to Improve FDA’s Management of Standardized Structured Scientific Data
Lilliam Rosario, PhD
Associate Director, Office of the Chief Scientist, FDA

Future State of Affairs: A Vision for a Day in the Life of a Reviewer
Tim Kropp, PhD
Toxicologist, Office of Oncology Drug Products, FDA

Panel Discussion
All Session Speakers and
Ron Wange
Pharmacologist, Division of Metabolism and Endocrinology Products, CDER, FDA
Theresa Allio
Pharmacologist, Division of Anti-Infective and Ophthalmology Products, CDER, FDA
Keith Peden
Microbiologist, Laboratory of Retroviruses, CBER, FDA

BREAKOUT SESSION 2
Preapproval – Clinical
CHAIRPERSON
Ghanshyam Gupta, PhD
Chief, Therapeutics Evaluation Branch
Office of Biostatistics and Epidemiology
CBER, FDA
This session will address the future informatics review state and the use of standardized data to improve the drug review process at both CBER and CDER. Conversion of legacy data for vaccine trials will be discussed, and a case study of the SDTM Vaccine Data Submission Pilot will also be presented.

The Future Desired Informatics Review State and Plans to Get There
Charles Cooper, MD
Medical Officer, Office of Translational Sciences, CDER, FDA

SDTM Pilot Submission: A Clinical Reviewer’s Perspective
Hon Sum Ko, MD
CBER, FDA

CBER’s SDTM Business Process and Implementation Plans
Amy Malla
Review Management, Office of the Director, CBER, FDA

Converting Legacy Data for Vaccine Trials
Jingyee Kou, PhD
Mathematical Statistician (Biomed), Vaccine Evaluation Branch, CBER, FDA

An SDTM Vaccine Data Submission Pilot: A Case Study
Richard C. Lowry, PhD
Manager, Scientific Programming – Vaccines, Merck & Co., Inc.

Panel Discussion
All Session Speakers
**BREAKOUT SESSION 3**

**Postmarket Safety**

**CHAIRPERSON**

Tarek A. Hammad, MD, PhD, MSc, MS  
Associate Director of Epidemiology, Division of Epidemiology, Office of Surveillance and Epidemiology, CDER, FDA

This session focuses on scientific issues pertinent to CDER/CBER postmarketing safety data. Stakeholders that are represented include FDA, industry, and academia. Presenters will address the needs, challenges, and solutions for three major aspects of handling postmarketing safety data: data efficiencies (storing, retrieving, achieving, and sharing), analytic approaches (tools and solutions for signal detection and signal strengthening/verification), and oversight of post-marketing inspections and data verification.

**Data Efficiencies and Analytic Approaches for Post-market Safety: An Introduction**

Tarek A. Hammad, MD, PhD, MSc, MS  
Associate Director of Epidemiology, Division of Epidemiology, Office of Surveillance and Epidemiology, CDER, FDA

**Signal Detection for Product Safety: A Biomedical Informatics Challenge**

Eric Brinsfield, MS  
Director Health and Life Science Solutions 
SAS Research and Development

Chris Diering  
Technical Architect Health and Life Sciences 
SAS Research and Development

**BREAKOUT SESSION 4**

**Product Quality**

**CHAIRPERSON**

Arzu Selen, PhD  
Associate Director, Biopharmaceutics, Office of New Drug Quality Assessment, CDER, FDA

Product quality efforts are rapidly advancing, and highlighting the need for state-of-the-art computational tools and technologies. The existing research and review oriented computational tools in the Office of Pharmaceutical Science display a wide range with respect to data handling and function. Implementation of new initiatives such as Quality-by-design emphasizes the need for greater access to data, sharing of knowledge and tools capable of linking data from multiple sources to enable rapid risk assessment.

In this forward-looking session, as we evaluate available computational tools and how they can be better utilized, additional computational tools suitable for molecular modeling, in vitro and in silico predictive modeling, simulation techniques and data mining will be explored. A platform/knowledgebase suitable for data storage and data analyses as described above, coupled with access to computational expertise and tools, will facilitate rapid, broad, and in-depth understanding of product quality data, enhance science- and risk-based decision making capabilities, support training, and knowledge transfer and sharing. The speakers, panel, and participants in the breakout session will review the current state and explore the future opportunities for product quality computational tools and technologies.

**Session and Speaker Introduction**

Christine Moore, PhD  
Acting Deputy Director, Office of New Drug Quality Assessment, CDER, FDA

**Database and Computational Needs in the Office of Biotechnology Products**

Steven Kozlowski, MD  
Director, Office of Biotechnology Products, CDER, FDA

**A New Method for Signal Detection with Application to AERS Data**

Ram Tiwari, PhD  
Associate Director for Statistical Science and Policy, CDER, FDA

**A Pattern Recognition Framework for Signal Identification**

Marianthi Markatou, MSc, PhD  
Affiliate Professor of Biomedical Informatics, Columbia University  
Former Scientific Advisor for CBER, FDA

**FDA's Sentinel Initiative**

Judith A. Racosim, MD, MPH  
Sentinel Initiative Scientific Lead 
OC, FDA

**Computational Science Needs for an Active Surveillance System: Lessons from the Observational Medical Outcomes Partnership (OMOP)**

Christian Reich, MD, PhD  
Project Manager IT 
Observational Medical Outcomes Partnership  
Foundation of the National Institutes of Health

**Ade Reporting and FDA/CDER's Inspection Program**

Gregg Claycamp  
Director, Division of Compliance 
CDER, FDA

**Panel Discussion**

All Session Speakers plus Panel Discussion Lead:  
Jeremy Rassen, ScD  
Instructor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women’s Hospital, Harvard Medical School
FDA decisions on drug approval depend on high-quality data from clinical trials. Validating and ensuring data quality begins upstream in the clinical trial process, while the study is ongoing so errors can be corrected in real time. These upstream assessments of data quality include monitoring of site data by sponsors or contract research organizations and auditing by quality assurance units. After the clinical trial is completed and a new drug application is submitted, the FDA uses inspections of clinical trial sites as an important method to assess data quality. Ensuring data quality both during and after clinical trials is necessarily risk-based due to limited resources. Advancements in computational methods have the potential to improve clinical trial data quality by the systematic assessment of risks to data quality and risk-based allocation of quality resources. This session will present innovative methods developed by government agencies (NIH, FDA), contract research organizations, and sponsors for detecting irregularities and patterns that signal risks to data quality and public health.

NIH/NCI Perspective: Real-time Monitoring of Clinical Trial Data
Edward D. Helton, PhD, MA
Associate Director, Center for Biomedical Informatics and Information Technology, National Cancer Institute, NIH

Contract Research Organization: Central Statistical Monitoring and Triggered Approach to Site Monitoring
Badhri N. Srinivasan
Vice President, Enterprise Transformation Unit, Quintiles Inc.

Use of Electronic Health Records and Electronic Data Capture for Real Time Monitoring
Dave Ibernon-Hurst
VP of Technical Strategy, CDISC

Sponsor Perspective: Innovative Tools for QA Auditing
Peter J. Schiemann, PhD
Global Head Quality Risk Management, Clinical Quality Assurance, F. Hoffmann-La Roche Ltd., Switzerland
C. Grant Simmons
Global Head, CQA Operations, Novartis Pharmaceuticals Corporation

Regulator Perspective: CDER Risk Model for Inspection Site Selection
Tom Moreno
Office of Compliance/DSI, CDER, FDA
Faiad Rahaman
Office of Compliance/DCRMS, CDER, FDA

Panel Discussion
All speakers above and
Lisa Kammerman, PhD
Mathematical Statistician, Office of Biostatistics
CDER, FDA

12:15-1:15 PM LUNCHEON AND EXHIBITS

1:15-2:25 PM SESSION 6 BREAKOUT SESSIONS continued

2:25-3:15 PM SESSION 7
Summary of Breakout Sessions
Chairpersons
Gary M. Gensinger
Deputy Director, Office of Business Process Support, CDER, FDA
Robert Powell, PharmD
Scientific Advisor, Roche Shanghai

Each group will offer a 10-minute presentation to summarize the discussion points of their breakout session.

3:15-3:45 PM REFRESHMENT BREAK AND EXHIBITS

3:45-4:30 PM SESSION 8
Collaborative Environments for Statistical Methodology Development – The Wiki Way
Chairperson
Mat Soukup, PhD
Mathematical Statistician, Division of Biometrics III, CDER, FDA

Specialized analytical tools are essential for statistical and graphical computing. Software packages come with standard statistical and graphical capabilities, but development of analytical and graphical methods for cutting-edge approaches tailored to clinical trial research often take years to implement. In order to implement advanced statistical methodologies, statisticians have to write and customize their own computer codes to execute these specialized data analyses. Under such a paradigm most of these user-created functions are not validated nor shared with statistical colleagues making such a paradigm inefficient in terms of implementing the latest statistical methods in a production environment.

In this session, our speakers will present a new environment that allows for collaborative development of specialized analytical tools based on the “wiki” concept. A “wiki” is a website that uses wiki software, allowing easy creation and editing of any number of interlinked Web pages, using a simplified markup language. The use of wiki will allow a community of users (eg, the regulatory agency, academia, and industry) to create, edit, and potentially validate program codes that can be used in the entire life cycle of drug development. A demo of the wiki will be presented along with a presentation of the evolution of the wiki and its advantages for use in clinical trial research.

The Use of Collaborative Environments - Where We Are Today and Where We Want to Be in the Future
Mat Soukup, PhD
Mathematical Statistician, Division of Biometrics III, CDER, FDA

The Use of CTSpedia: Revisiting the Past to Designing it for the Future
Laurel A. Beckett, PhD
University of California, Davis

4:30-5:00 PM SUMMARY AND NEXT STEPS

5:00 PM CONFERENCE ADJOURNED
# DIA/FDA CDER/CBER Computational Science Annual Meeting

**Event #10014 • March 22-23, 2010**  
Bethesda North Marriott Hotel and Conference Center, Bethesda, MD, USA

## Contact Information

**Event Information:** Contact Benjamin Zaitz at the DIA office by telephone +1.215.293.5803, fax +1.215.293.5937 or email Benjamin.Zaitz@diahome.org.

**Exhibits Information:** Contact Shannon Lewis at the DIA office by telephone +1.215.442.6149, fax +1.215.442.6199 or email Shannon.Lewis@diahome.org.

## Registration Fees

Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

<table>
<thead>
<tr>
<th>Industry Fee</th>
<th>US $1295 □</th>
</tr>
</thead>
<tbody>
<tr>
<td>Join DIA now to save on future events and to receive all the benefits of membership.</td>
<td>MEMBERSHIP</td>
</tr>
<tr>
<td>Visit <a href="http://www.diahome.org/Membership">www.diahome.org/Membership</a></td>
<td>US $140 □</td>
</tr>
</tbody>
</table>

## Discount Fees

- Government (Full-time)  
  US $390 □
- Charitable Nonprofit/Academia (Full-time)  
  US $650 □

## PAYMENT OPTIONS:

- **Register online at [www.diahome.org](http://www.diahome.org)** or check payment method.

- **CREDIT CARD** number may be faxed to: +1.215.442.6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

- **Card #**

- **Exp Date**

- **Name (printed)**

- **Signature**

- **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

- **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.

## CANCELLATION POLICY: On or before March 15, 2010

**Administrative fee that will be withheld from refund amount:**

- **Member or Nonmember** = $200
- **Government or Academy or Nonprofit (Member or Nonmember)** = $100
- **Tutorial (if applicable)** = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations.

You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

**DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.**

## Please check the applicable category:

- [ ] **Academia**
- [ ] **Government**
- [ ] **Industry**
- [ ] **CSO**
- [ ] **Student**

(If DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.)

---

**TRAVEL AND HOTEL** The most convenient airport is Ronald Reagan Washington National Airport and attendees should make airline reservations as early as possible to ensure availability. The Bethesda North Marriott Hotel and Conference Center is holding a block of rooms at the reduced rate below until February 28, 2010, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

- **Single $226**
- **Double $226**

Please contact the Bethesda North Marriott Hotel and Conference Center by telephone at +1.800.228.9290 or +1.301.822.9200 and mention the DIA event. The hotel is located at 5701 Marinelli Road, Bethesda, MD, 20852, USA.

**Please check the applicable category:**

- [ ] **Academia**
- [ ] **Government**
- [ ] **Industry**
- [ ] **CSO**
- [ ] **Student**

(If DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.)

---

**Participants with Disabilities:** DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.